Neurobiology of Cancer: Introduction of New Drugs in the Treatment and Prevention of Cancer
Research on the neurobiology of cancer, which lies at the border of neuroscience and oncology, has elucidated the mechanisms and pathways that enable the nervous system to modulate processes associated with cancer initiation and progression. This research has also shown that several drugs which modu...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-06-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/22/11/6115 |
| _version_ | 1797531167881166848 |
|---|---|
| author | Boris Mravec |
| author_facet | Boris Mravec |
| author_sort | Boris Mravec |
| collection | DOAJ |
| description | Research on the neurobiology of cancer, which lies at the border of neuroscience and oncology, has elucidated the mechanisms and pathways that enable the nervous system to modulate processes associated with cancer initiation and progression. This research has also shown that several drugs which modulate interactions between the nervous system and the tumor micro- and macroenvironments significantly reduced the progression of cancer in animal models. Encouraging results were also provided by prospective clinical trials investigating the effect of drugs that reduce adrenergic signaling on the course of cancer in oncological patients. Moreover, it has been shown that reducing adrenergic signaling might also reduce the incidence of cancer in animal models, as well as in humans. However, even if many experimental and clinical findings have confirmed the preventive and therapeutic potential of drugs that reduce the stimulatory effect of the nervous system on processes related to cancer initiation and progression, several questions remain unanswered. Therefore, the aim of this review is to critically evaluate the efficiency of these drugs and to discuss questions that need to be answered before their introduction into conventional cancer treatment and prevention. |
| first_indexed | 2024-03-10T10:40:05Z |
| format | Article |
| id | doaj.art-7f5795f23e11431ba0efc63cc177e1a9 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T10:40:05Z |
| publishDate | 2021-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-7f5795f23e11431ba0efc63cc177e1a92023-11-21T23:00:40ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-06-012211611510.3390/ijms22116115Neurobiology of Cancer: Introduction of New Drugs in the Treatment and Prevention of CancerBoris Mravec0Institute of Physiology, Faculty of Medicine, Comenius University in Bratislava, 813 72 Bratislava, SlovakiaResearch on the neurobiology of cancer, which lies at the border of neuroscience and oncology, has elucidated the mechanisms and pathways that enable the nervous system to modulate processes associated with cancer initiation and progression. This research has also shown that several drugs which modulate interactions between the nervous system and the tumor micro- and macroenvironments significantly reduced the progression of cancer in animal models. Encouraging results were also provided by prospective clinical trials investigating the effect of drugs that reduce adrenergic signaling on the course of cancer in oncological patients. Moreover, it has been shown that reducing adrenergic signaling might also reduce the incidence of cancer in animal models, as well as in humans. However, even if many experimental and clinical findings have confirmed the preventive and therapeutic potential of drugs that reduce the stimulatory effect of the nervous system on processes related to cancer initiation and progression, several questions remain unanswered. Therefore, the aim of this review is to critically evaluate the efficiency of these drugs and to discuss questions that need to be answered before their introduction into conventional cancer treatment and prevention.https://www.mdpi.com/1422-0067/22/11/6115β-blockersadrenergicantibodies against nerve growth factoraspirincancerelectroceuticals |
| spellingShingle | Boris Mravec Neurobiology of Cancer: Introduction of New Drugs in the Treatment and Prevention of Cancer International Journal of Molecular Sciences β-blockers adrenergic antibodies against nerve growth factor aspirin cancer electroceuticals |
| title | Neurobiology of Cancer: Introduction of New Drugs in the Treatment and Prevention of Cancer |
| title_full | Neurobiology of Cancer: Introduction of New Drugs in the Treatment and Prevention of Cancer |
| title_fullStr | Neurobiology of Cancer: Introduction of New Drugs in the Treatment and Prevention of Cancer |
| title_full_unstemmed | Neurobiology of Cancer: Introduction of New Drugs in the Treatment and Prevention of Cancer |
| title_short | Neurobiology of Cancer: Introduction of New Drugs in the Treatment and Prevention of Cancer |
| title_sort | neurobiology of cancer introduction of new drugs in the treatment and prevention of cancer |
| topic | β-blockers adrenergic antibodies against nerve growth factor aspirin cancer electroceuticals |
| url | https://www.mdpi.com/1422-0067/22/11/6115 |
| work_keys_str_mv | AT borismravec neurobiologyofcancerintroductionofnewdrugsinthetreatmentandpreventionofcancer |